ZNTL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZNTL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Zentalis Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was $3.68. Zentalis Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 71.15 Mil. Therefore, Zentalis Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was $261.83 Mil.
Zentalis Pharmaceuticals's quarterly market cap declined from Mar. 2024 ($1,119.15 Mil) to Jun. 2024 ($290.83 Mil) and declined from Jun. 2024 ($290.83 Mil) to Sep. 2024 ($261.83 Mil).
Zentalis Pharmaceuticals's annual market cap declined from Dec. 2021 ($3,823.97 Mil) to Dec. 2022 ($1,193.90 Mil) and declined from Dec. 2022 ($1,193.90 Mil) to Dec. 2023 ($1,072.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zentalis Pharmaceuticals's Enterprise Value for Today is $-221.81 Mil.
The historical data trend for Zentalis Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zentalis Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Market Cap | Get a 7-Day Free Trial | - | 2,131.62 | 3,823.97 | 1,193.90 | 1,072.10 |
Zentalis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1,417.06 | 1,072.10 | 1,119.15 | 290.83 | 261.83 |
For the Biotechnology subindustry, Zentalis Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Zentalis Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Zentalis Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $15.15 | * | 70.766 | |
= | $1,072.10 |
Zentalis Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as
Market Cap (Q: Sep. 2024 ) | = | Share Price (Q: Sep. 2024 ) | * | Shares Outstanding (EOP) (Q: Sep. 2024 ) |
= | $3.68 | * | 71.150 | |
= | $261.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zentalis Pharmaceuticals (NAS:ZNTL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrea Paul | officer: General Counsel | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Jan Skvarka | director | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Cam Gallagher | director | 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121 |
Diana Hausman | director | C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121 |
Melissa B, Epperly | officer: Chief Financial Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Kimberly Blackwell | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
David Michael Johnson | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Carrie Brownstein | officer: Chief Medical Officer | 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701 |
Kevin D. Bunker | officer: Chief Operating Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Iris Roth | officer: Chief Operating Officer | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Anthony Y Sun | director, officer: President & CEO | C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106 |
Alexis Pinto | officer: Chief Legal Officer | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Dimitris Voliotis | officer: SVP, Clinical Development | C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Enoch Kariuki | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Marketwired • 11-13-2024
By Marketwired • 12-02-2024
By PRNewswire • 02-04-2025
By GuruFocus News • 02-14-2025
By PRNewswire • 02-11-2025
By Marketwired • 09-09-2024
By Marketwired • 11-02-2024
By Marketwired • 01-28-2025
By Business Wire • 08-19-2024
By Marketwired • 11-21-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.